<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Project 4 – Clinical Evaluation of Agents Targeting the Tumor Microenvironment</title>
  <link rel="stylesheet" href="../style.css" />
</head>
<body>
  <header>
    <h1>Roberto Pili Lab at the University at Buffalo</h1>
    <nav>
      <ul>
        <li><a href="../index.html">Overview</a></li>
        <li><a href="../team.html">Team</a></li>
        <li><a href="../projects.html" class="active">Research Projects</a></li>
        <li><a href="../contact.html">Contact</a></li>
      </ul>
    </nav>
  </header>

  <main>
    <section>
      <h2>Clinical Evaluation of Agents Targeting the Tumor Microenvironment</h2>
      <p>
        Our group has been involved in the clinical testing of several agents targeting the tumor microenvironment, including antiangiogenics and immunomodulators. These studies have generated the preliminary data for further development of these therapeutic strategies.
      </p>
      <h3>Key Publications</h3>
      <ul>
        <li>
          Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. 
          <i>Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.</i> 
          J Clin Oncol. 2011 Oct 20;29(30):4022-8. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/21931019/" target="_blank">PMID: 21931019</a>
        </li>
        <li>
          Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. 
          <i>Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.</i> 
          Br J Cancer. 2012 Jan 3;106(1):77-84. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/22134508/" target="_blank">PMID: 22134508</a>
        </li>
        <li>
          Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. 
          <i>Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.</i> 
          Clin Cancer Res. 2010 May 15;16(10):2906-14. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/20460477/" target="_blank">PMID: 20460477</a>
        </li>
        <li>
          Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA. 
          <i>Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.</i> 
          Br J Cancer. Mar 28;116(7):874-883. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/28222071/" target="_blank">PMID: 28222071</a>
        </li>
      </ul>
      <p>
        Complete List of Published Work in My Bibliography: 
        <a href="https://pubmed.ncbi.nlm.nih.gov/?term=pili++r&sort=pubdate" target="_blank">PubMed Bibliography</a>
      </p>
    </section>
  </main>

  <footer>
    <p>© 2025 Roberto Pili Lab | University at Buffalo</p>
  </footer>
</body>
</html>